Cargando…

Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancer

Cetuximab plus chemotherapy for advanced gastric cancer (GC) shows an active result in phase 2 trials. Unfortunately, Combination of cetuximab does not provide enough benefit to chemotherapy alone in phase 3 trials. Studies have demonstrated that berberine can suppress the activation of EGFR in tumo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Junxiong, Yang, Shuo, Cai, Xiqiang, Dong, Jiaqiang, Chen, Zhangqian, Wang, Rui, Zhang, Song, Cao, Haichao, Lu, Di, Jin, Tong, Nie, Yongzhan, Hao, Jianyu, Fan, Daiming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342797/ https://www.ncbi.nlm.nih.gov/pubmed/27738318 http://dx.doi.org/10.18632/oncotarget.12589

Ejemplares similares

Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR
por: Du, Feng, et al.
Publicado: (2019)

A CGA/EGFR/GATA2 positive feedback circuit confers chemoresistance in gastric cancer
por: Cao, Tianyu, et al.
Publicado: (2022)

DNMT1 expression partially dictates 5-Azacytidine sensitivity and correlates with RAS/MEK/ERK activity in gastric cancer cells
por: Chen, Zhangqian, et al.
Publicado: (2023)

Acacetin exerts antitumor effects on gastric cancer by targeting EGFR
por: Zhang, Guangtao, et al.
Publicado: (2023)

Biased random walk model for the prioritization of drug resistance associated proteins
por: Guo, Hao, et al.
Publicado: (2015)

The Role of the Slit/Robo Signaling Pathway
por: Tong, Mingfu, et al.
Publicado: (2019)

Design, synthesis and antitumor activity of 5-trifluoromethylpyrimidine derivatives as EGFR inhibitors
por: Zuo, Yaqing, et al.
Publicado: (2022)

Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells
por: FUKUDA, KAZUMASA, et al.
Publicado: (2011)

BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer
por: Fan, Fushun, et al.
Publicado: (2020)

Design, synthesis and in vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment
por: Le, Yi, et al.
Publicado: (2020)

Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity
por: Sonousi, Amr, et al.
Publicado: (2022)

MicroRNA-149 Inhibits Proliferation and Cell Cycle Progression through the Targeting of ZBTB2 in Human Gastric Cancer
por: Wang, Ying, et al.
Publicado: (2012)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
por: Shi, Chen, et al.
Publicado: (2023)

ECT2 Increases the stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer
por: Wang, Junxiong, et al.
Publicado: (2021)

VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer
por: Yu, Junxian, et al.
Publicado: (2023)

Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
por: Zhang, Guowei, et al.
Publicado: (2017)

Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent
por: Liu, Wei, et al.
Publicado: (2015)

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
por: Du, Xiaojing, et al.
Publicado: (2021)

EGFR alterations in glioblastoma play a role in antitumor immunity regulation
por: Li, Xiao-Peng, et al.
Publicado: (2023)

EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: A potential mechanism of EGFR-driven antagonism of apoptosis
por: Cao, Xinyu, et al.
Publicado: (2011)

EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction
por: Kumarakulasinghe, Nesaretnam Barr, et al.
Publicado: (2016)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
por: Qin, YanRu, et al.
Publicado: (2020)

LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo
por: Liu, Yingqiang, et al.
Publicado: (2021)

The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors
por: Chang, Xiaofei, et al.
Publicado: (2013)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Reversal of EGFR inhibitors’ resistance by co-delivering EGFR and integrin αvβ3 inhibitors with nanoparticles in non-small cell lung cancer
por: He, Fei, et al.
Publicado: (2019)

RANKL/RANK promotes the migration of gastric cancer cells by interacting with EGFR
por: Wan, Xing, et al.
Publicado: (2020)

Antitumor effects of erlotinib in combination with berberine in A431 cells
por: Cuan, Xiangdan, et al.
Publicado: (2023)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Effects of EGFR Inhibitor on Helicobacter pylori Induced Gastric Epithelial Pathology in Vivo
por: Crabtree, Jean E., et al.
Publicado: (2013)

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
por: Wang, Wenxian, et al.
Publicado: (2016)

The transcription factor FOXO4 is down-regulated and inhibits tumor proliferation and metastasis in gastric cancer
por: Su, Linna, et al.
Publicado: (2014)

Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR ‐mutated lung cancer
por: Ito, Takashi, et al.
Publicado: (2021)

Computational Probing the Methylation Sites Related to EGFR Inhibitor-Responsive Genes
por: Yuan, Rui, et al.
Publicado: (2021)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Differential Transcriptional Effects of EGFR Inhibitors
por: Blumenberg, Miroslav
Publicado: (2014)

Characterization of Covalent-Reversible EGFR Inhibitors
por: Smith, Steven, et al.
Publicado: (2017)

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
por: Yoshizawa, Takahiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ktu8npocd5agfr9652pvgm0ki5